Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 140 Leukemia 132 Lymphoma 90 Leukemia, Myeloid, Acute 62 Myelodysplastic Syndromes 47 Burkitt Lymphoma 46 Lymphoma, Non-Hodgkin 44 Lymphoma, Large B-Cell, Diffuse 37 Breast Neoplasms 37 Lymphoma, Mantle-Cell 33 Leukemia, Lymphocytic, Chronic, B-Cell 33 Hodgkin Disease 32 Multiple Myeloma 29 Congenital Abnormalities 29 Myeloproliferative Disorders 27 Lymphoma, Follicular 27 Leukemia, Myeloid, Accelerated Phase 27 Graft vs Host Disease 27 Leukemia, Myelomonocytic, Chronic 25 Lymphoma, Large-Cell, Immunoblastic 24 Leukemia, Myeloid, Chronic-Phase 24 Blast Crisis 24 Lymphoma, B-Cell, Marginal Zone 22 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 20 Anemia, Refractory, with Excess of Blasts 20 Recurrence 18 Primary Myelofibrosis 17 Neoplasms, Plasma Cell 17 Dendritic Cell Sarcoma, Interdigitating 17 Osteosarcoma 16

Interventions

Vinblastine 1 Methotrexate 1 Cyclophosphamide 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Survival Without Progression × Methotrexate × Clear all

NCT01285817 2023-03-13

SFCE METRO 01

Assistance Publique Hopitaux De Marseille

Phase 2 Completed

Survival Without Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡